Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Open-Label, Single-Center Randomized Trial.
Pancreas
; 50(8): 1236-1242, 2021 09 01.
Article
em En
| MEDLINE
| ID: mdl-34714289
ABSTRACT
METHODS:
This was single-center, open-label, randomized trial. Patients who were undergoing ERCP and who were at high risk for the development of PEP were selected for the study. Patients were randomized into 3 treatment groups diclofenac suppository group, RL group, and a combination group.RESULTS:
Eight of 57 patients (14.03%) in the diclofenac group, 9 of 57 patients (15.78%) in the RL group, and 6 of 57 patients (10.52%) in the combination group developed PEP. The incidence of PEP between the three groups was not statistically significant (P = 0.70). Serum amylase level of >252 U/L had 91.3% sensitivity and 92.6% specificity for the diagnosis of PEP.CONCLUSIONS:
Post-ERCP pancreatitis is usually mild to moderate 95% times. Female sex, age younger than 50 years, a benign indication of ERCP, and low bilirubin levels have higher chances of PEP. A combination of rectal diclofenac and hydration with RL does not offer better protection for PEP, as compared with individual prophylaxis.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pancreatite
/
Diclofenaco
/
Colangiopancreatografia Retrógrada Endoscópica
/
Lactato de Ringer
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article